Verastem, Inc. - Special Call Transcript
Good morning, and welcome to the Verastem Oncology Investor Conference Call on Wednesday, September 16, 2020. (Operator Instructions) Please be advised that this call is being recorded at the company's request and will be available on the company's website for a period of 90 days from today.
At this time, I would like to introduce Mr. John Doyle, Vice President of Investor Relations and Finance at Verastem Oncology. Please go ahead.
Welcome, everyone, and thank you for joining us this morning. With me today to discuss the updated clinical data from the ongoing Phase I/II FRAME study investigated in the combination of VS-6766 and defactinib in low-grade serous ovarian cancer are: Brian Stuglik, Chief Executive Officer; Dan Paterson, President and Chief Operating Officer; Rob Gagnon, Chief Financial Officer; and Dr. Rachel Grisham, Medical Oncologist, Memorial Sloan Kettering Cancer Center and the Co-Principal Investigator of the upcoming registration-directed trial in low-grade serous ovarian cancer.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |